Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Sun, Ren ^a   Wang, Liya ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

6 thioguanine; Growth inhibition; Hypoxanthine guanine phosphoribosyl transferase; Mycoplasma pneumoniae; Thymidine kinase; Trifluorothymidine

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZACITIDINE; AZATHIOPRINE; CIDOFOVIR; DIPYRIDAMOLE; FLOXURIDINE; FLUDARABINE PHOSPHATE; GANCICLOVIR; GEMCITABINE; GUANINE; HYPOXANTHINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IDOXURIDINE; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; PENTOXIFYLLINE; PYRIMETHAMINE; RIBAVIRIN; STAVUDINE; THYMIDINE KINASE; TIOGUANINE; TRIFLURIDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; DRUG METABOLISM; DRUG UPTAKE; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; NONHUMAN; NUCLEOTIDE METABOLISM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; UPREGULATION;

ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA PNEUMONIAE; NUCLEOSIDES;

MYCOPLASMA; MYCOPLASMA PNEUMONIAE;

EID: 84881044672     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-184     Document Type: Article

References (52)

1. Molecular biology and pathogenicity of Mycoplasmas. Razin S, Yogev D, Naot Y, Microbiol Mol Biol Rev 1998 62 1094 1156 9841667 (Pubitemid 28558294)
2. Mycoplasma pneumoniae and its role as a human pathogen. Waites KB, Talkington DF, Clin Microbiol Rev 2004 17 697 728 10.1128/CMR.17.4.697-728.2004 15489344 (Pubitemid 39372513)
3. Pathogenesis of extrapulmonary manifestations of Mycoplasma penumoniae infection with special reference to pneumonia. Narita M, J infec Chemother 2010 16 162 169 10.1007/s10156-010-0044-x
4. Surveillance status and recent data for Mycoplasam pneumoniae infection in the European Union and European Economic area, January 2012. Lenglet A, Herrado Z, Magiorakos A, Leitmeyer K, Coulombier D, Euro Surveill 2012 17 2 7
5. Clonal spread of Mycoplasma pneumoniae in primary school, Bordeaux, France. Pereyre S, Renaudin H, Charron A, Bebear C, Emerg Infect Dis 2012 18 343 345 10.3201/eid1802.111379 22305177
6. Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy. Lung D, Chan Y, Kwong L, Que T, Hong Kong Med J 2011 17 407 409 21979480
7. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Hsieh Y, Tsao K, Huang C, Tong S, Winchell J, Huang Y, Shia S, Lai S, Lin T, Pediatr Infect Dis 2012 31 208 209 10.1097/INF.0b013e318234597c
8. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. Morozumi M, Takahashi T, Ubukata K, J Infec Chemother 2010 16 78 86 10.1007/s10156-009-0021-4
9. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Bebear C, Pereyre S, Peuchant O, Future Microbiol 2011 6 423 431 10.2217/fmb.11.18 21526943
10. Rising rates of macrolode-resistant Mycoplasma pneumoniae in the central United State. Yamada M, Buller R, Bledsoe S, Storch G, Pediatr Infect Dis 2012 31 409 10.1097/INF.0b013e318247f3e0
11. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, Zhang J, Antimicrob Agents Chemother 2012 56 1108 1109 10.1128/AAC.05627-11 22106216
12. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Cao B, Zhao C, Yin Y, Zhao F, Song S, Bai L, Zhang J, Liu Y, Zhang Y, Wang H, Wang C, Clin Infect Dis 2010 51 189 194 10.1086/653535 20540621
13. Anticancer and antiviral sulfonamides. Scozzafava A, Owa T, Mastrolorenzo A, Supuran C, Curr Med Chem 2003 10 925 953 10.2174/0929867033457647 12678681 (Pubitemid 36582239)
14. Folate-based thymidylate synthase inhibitors as anticancer drugs. Jackman A, Calvert A, Ann Oncol 1995 6 871 881 8624289
15. Structure-based studies on species-specific inhibition of thymidylate synthase. Costi M, Tondi D, Rinaldi M, Barlocco D, Pecorari P, Soragni F, Venturelli A, Stroud R, Biochim Biophys Acta 2002 1587 206 214 10.1016/S0925-4439(02)00083-2 12084462 (Pubitemid 34655789)
16. Perspectives on the development of acyclic nucleoside analogs as antiviral drugs. Lee W, Martin J, Antiviral Res 2006 71 254 259 10.1016/j.antiviral.2006.05.020 16837073 (Pubitemid 44223778)
17. HIV-1 antiretroviral drug therapy. Arts E, Hazuda D, Cold Spring Harb Perspect Med 2012 2 1 23
18. Evaluation of Bacillus anthracis thymidine kinase as a potential target for the development of antibacterial nucleoside analogs. Carnrot C, Vogel S, Byun Y, Wang L, Tjarks W, Eriksson S, Phipps A, Biol Chem 2006 387 1575 1581 17132103 (Pubitemid 44837582)
19. Synthesis and antimicrobial activity of some novel nucleoside analogues of adenosine and 1,3-dideazaadenosine. Srivastava R, Bhargava A, Singh R, Bioorg Med Chem Lett 2007 17 6239 6244 10.1016/j.bmcl.2007.09.028 17890082 (Pubitemid 47554692)
20. Drug design and identification of potent leads against Mycobacterium tuberculosis thymidine monophosphate kinase. Van Calenberg S, Pochet S, Munier-Lehmann H, Curr Top Med Chem 2012 12 694 705 10.2174/156802612799984580 22283813
21. Structure guided development of novel thymidine mimetics targeting Pseudomonas aeruginosa thymidylate kinase: from hit to lead generation. Choi J, Plummer M, Starr J, Desbonnet C, Soutter H, Chang J, Miller J, Dillman K, Miller A, Roush W, J Med Chem 2012 55 852 870 10.1021/jm201349f 22243413
22. Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK). Martinez-Botella G, Breen J, Duffy J, Dumas J, Geng B, Gowers I, Green O, Guler S, Hentemann M, Hernandez-Huan F, Joseph-McCarthy D, Kawatkar S, Larsen N, Lazari O, Loch J, Macritchie J, McKenzie A, Newman J, Olivier N, Otterson L, Owens A, Read J, Sheppard D, Keating T, J Med Chem 2012 55 10010 10021 10.1021/jm3011806 23043329
23. In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound. Keating T, JV N, Olivier N, Otterson L, Andrews B, Boriack-Sjodin P, Breen J, Dolg P, Dumas J, Gangl E, Green O, Guler S, Hentemann M, Joseph-McCarthy D, Kawatkar S, Kutschke A, Loch J, McKenzie A, Pradeepan S, Prasad S, Martinez-Botella G, ACS Chem Biol 2012 7 1866 1872 10.1021/cb300316n 22908966
24. Pathways of nucleotide biosynthesis in Mycoplasma mycoides subsp. mycoides. Mitchell A, Finch L, J Bacteriol 1977 130 1047 1054 324972 (Pubitemid 8123995)
25. Enzymes of purine metabolism in Mycoplasma mycoides subsp. mycoides. Mitchell A, Sin I, Finch L, J Bacteriol 1978 134 706 712 207675 (Pubitemid 8360877)
26. Enzymes of pyrimidine metabolism in Mycoplasma mycoides subsp. mycoides. Mitchell A, Finch L, J Bacteriol 1979 137 1073 1080 220209 (Pubitemid 9198869)
27. Comparative metabolism of Mesoplasma, Entomoplasma, Mycoplasma, and Acholeplasma. Pollack J, Williams M, Banzon J, Jones M, Harvey L, Tully J, Int J Syst Bacteriol 1996 46 885 890 10.1099/00207713-46-4-885 8863414 (Pubitemid 26339208)
28. The comparative metabolism of the Mollicutes (Mycoplasmas): the utility for taxonomic classification and the relationship of putative gene annotation and phylogeny to enzymatic function in the smallest free-living cells. Pollack J, Williams M, McElhaney R, Crit Rev Microbiol 1997 23 269 354 10.3109/10408419709115140 9439886 (Pubitemid 28037641)
29. Novel deoxynucleoside-phosphorylating enzymes in Mycoplasmas: evidence for efficient utilization of deoxynucleosides. Wang L, Westberg J, Bölske G, Eriksson S, Mol Microbiol 2001 42 1065 1073 10.1046/j.1365-2958.2001.02700.x 11737647 (Pubitemid 33078387)
30. Molecular characterization of thymidine kinase from Ureaplasma urealyticum: nucleoside analogues as potent inhibitors of mycoplasma growth. Carnrot C, Wehelie R, Eriksson S, Bölske G, Wang L, Mol Microbiol 2003 50 771 780 10.1046/j.1365-2958.2003.03717.x 14617140 (Pubitemid 37372242)
31. Upregulation of thymidine kinase activity compensates for loss of thymidylate synthase activity in Mycoplasma pneumoniae. Wang L, Hames C, Schmidt S, Stülke J, Mol Microbiol 2010 77 1502 1511 10.1111/j.1365-2958.2010. 07298.x 20860090
32. Impact of genome reduction on bacterial metabolism and its regulation. Yus E, Maier T, Michalodimitrakis K, van Noort V, Yamada T, Chen W, Wodke J, Güell M, Martinez S, Bourgeois R, Kühner S, Raineri E, Letunic I, Kalinina O, Rode M, Herrmann R, Gutierrez-Gallego R, Russell R, Gavin A, Bork P, Serrano L, Science 2009 326 1263 1268 10.1126/science.1177263 19965476
33. Global transposon mutagenesis and a minimal Mycoplasma genome. Hutchison C, Peterson S, Gill S, Cline R, White O, Fraser C, Smith HO, Venter JC, Science 1999 286 2165 2169 10.1126/science.286.5447.2165 10591650 (Pubitemid 129516293)
34. Essential genes of a minimal bacterium. Glass JI, Assad-Garcia N, Alperovich N, Yooseph S, Lewis MR, Maruf M, Hutchison CA, Smith HO, Venter JC, Proc Natl Acad Sci USA 2006 103 425 430 10.1073/pnas.0510013103 16407165 (Pubitemid 43122417)
35. Growth inhibition of Mycoplasma by nucleoside analogues. Wehelie R, Eriksson S, Bölske G, Wang L, Nucleosides, Nucleotides & Nucleic Acid 2004 23 1499 1502 10.1081/NCN-200027714 23896889 (Pubitemid 39625951)
36. Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism. Egeblad L, Welin M, Flodin S, Gräslund S, Wang L, Balzarini J, Eriksson S, Nordlund P, PLoS One 2012 7 37724 10.1371/journal.pone.0037724 22662200
37. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, Pousette A, Almer S, Gut 2006 55 1423 1431 10.1136/gut.2005.074930 16543290 (Pubitemid 44476786)
38. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2'-deoxyuridylic acid. Santi D, Sakai T, Biochemistry 1971 10 3598 3607 10.1021/bi00795a018 5146573
39. Structures of thymidine kinase 1 of human and mycoplasmic origin. Welin M, Kosinska U, Mikkelsen N, Carnrot C, Zhu C, Wang L, Eriksson S, Munch-Petersen B, Eklund H, Proc Natl Acad Sci USA 2004 101 17970 17975 10.1073/pnas. 0406332102 15611477 (Pubitemid 40054059)
40. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. Wang L, Munch-Petersen B, Herrström Sjöberg A, Hellman U, Bergman T, Jörnvall H, Eriksson S, FEBS Lett 1999 443 170 174 10.1016/S0014-5793(98) 01711-6 9989599 (Pubitemid 29078626)
41. Expression of human mitochondrial thymidine kinase in Escherichia coli: correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth. Wang J, Su C, Neuhard J, Eriksson S, Biochem Pharmacol 2000 59 1583 1588 10.1016/S0006-2952(00)00285-9 10799656 (Pubitemid 30229892)
42. Use of pathway analysis and genome context methods for functional genomics of Mycoplasma pneumoniae nucleotide metabolism. Pachkov M, Dandekar T, Korbel J, Bork P, Schuster S, Gene 2007 396 215 225 10.1016/j.gene.2007.02.033 17467928 (Pubitemid 46935396)
43. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leikopenia in the treatment of inflammatroy bowel disease. Ding L, Zhang F, Liu H, Gao X, Bi H, Wang XQ, Chen B, Zhang Y, Zhao L, Zhong G, Hu P, Chen M, Huang M, Inflamm Bowel Dis 2012 18 63 73 10.1002/ibd.21676 21381155
44. Structural and function studies of the human phosphoribosyltransferase domain containing protein 1. Welin M, Egeblad L, Johansson A, Stenmark P, Wang L, Flodin S, Nyman T, Trésaugues L, Kotenyova T, Johansson I, Eriksson S, Eklund H, Nordlund P, FEBS J 2010 277 4920 4930 10.1111/j.1742-4658.2010.07897. x 21054786
45. Physiological concentrations of purines and pyrimidines. Traut T, Mol Cell Biochem 1994 140 1 22 10.1007/BF00928361 7877593 (Pubitemid 24379884)
46. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases. Cesnek M, Hockova D, Holy A, Dracinsky M, Baszczynski O, Jersey J, DT K, Guddat L, Bioorg Med Chem 2012 20 1076 1089 10.1016/j.bmc.2011.11.034 22178188
47. Prodrug activation by Cryptosporidium thymidine kinase. Sun X, Sharling L, Muthalagi M, Mudeppa D, Pankiewicz K, Felczak K, Rathod P, Mead J, Striepen B, Hedstrom L, J Biol Chem 2010 285 15916 15922 10.1074/jbc.M110.101543 20231284
48. Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria. Sandrini M, Shannon O, Clausen A, Björck L, Piskur J, Antimicrob Agents Chemother 2007 51 2726 2732 10.1128/AAC.00081-07 17526755 (Pubitemid 47206206)
49. Dual phosphorylation of Mycoplasma pneumoniae HPr by enzyme I and HPr kinase suggests an extended phosphoryl group susceptibility of HPr. Halbedel S, Stülke J, FEMS Microbiol Lett 2004 247 193 198 (Pubitemid 40799192)
50. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri Y, Sasaky Y, Arakawa Y, Sasaky T, Microbiol Immunol 2001 45 617 620 11592636 (Pubitemid 32785787)
51. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma. Sharif H, von Euler H, Westberg S, He E, Wang L, Eriksson S, Vet J 2012 194 40 47 10.1016/j.tvjl.2012.03.006 22516918
52. The role of Ureaplasma nucleoside monophosphate kinases in the synthesis of nucleoside triphosphates. Wang L, FEBS J 2007 274 1983 1990 10.1111/j.1742-4658.2007.05742.x 17355283 (Pubitemid 46587998)